Generated by AI
Liquidia Corporation is a biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for rare cardiopulmonary diseases. The company’s current portfolio centers on treatments for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, supported by its proprietary PRINT particle-engineering platform, which is designed to create precise drug particles for inhaled and other advanced delivery formats. Liquidia’s work spans product development, manufacturing, and commercialization, giving it a role across the full lifecycle of specialty respiratory medicines. Its marketed and investigational programs are aimed at patients with challenging respiratory and vascular conditions, positioning the company within the rare-disease and specialty pharmaceutical markets. Liquidia Corporation is headquartered in Morrisville, North Carolina.
Website419 Davis Drive
Morrisville, NC, 27560
United States
The latest articles about LQDA.
The bull case for LQDA: YUTREPIA can keep generating PAH revenue, while L606 could offer another path into PH-ILD if trials and review succeed.
Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.
Summary of Nov 12's posts. Generated by AI.
Summary of Oct 26's posts. Generated by AI.
Summary of Nov 10's posts. Generated by AI.
Investors talking about LQDA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.